Alliance Global Partners analyst Aaron Grey downgrades Neptune Wellness Solns (NASDAQ:NEPT) from Buy to Neutral.
May 1, 1:00 PM
Piper Sandler has decided to maintain its Overweight rating of TechnipFMC (NYSE:FTI) and lower its price target from…
LIXTE Biotechnology’s Preclinical Results In Collaboration With Netherlands Cancer Institute Reveal Novel Mechanism By Which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness Of Immunotherapy And Chemotherapy
July 17, 8:39 AM
Results Provide Striking Molecular Evidence that Inhibiting PP2A with LB-100 Sensitizes Cancer Cells to Immunotherapy and Chemotherapy PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE
April 4, 1:00 PM
Oppenheimer has decided to maintain its Outperform rating of MSCI (NYSE:MSCI) and raise its price target from $575.00…